SCHEMBL365557

SCHEMBL365557

CCOC(=O)C(=CN(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.53
NPSR1 Q6W5P4 3/20 0.48
GLO1 Q04760 1/20 0.48
ALDH1A1 P00352 3/20 0.47
CYP2D6 P10635 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 5/20 0.39
GAA P10253 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
S1PR4 O95977 1/20 0.39
S1PR1 P21453 1/20 0.39
MAPK1 P28482 1/20 0.39
DHODH Q02127 3/20 0.38
USP2 O75604 1/20 0.38
IDE P14735 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230226 0.90 CYP2C9 (0.58) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL5902214 0.84 GLO1 (0.64) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL120746 0.84 GLO1 (0.64) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL932966 0.84 CYP2C9 (0.53) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL932967 0.84 CYP2C9 (0.53) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL120745 0.84 GLO1 (0.64) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL15565954 0.84 CYP2C9 (0.53) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL18733161 0.82 CYP2C9 (0.51) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL5902803 0.82 CYP2C9 (0.51) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL4099809 0.82 CYP2C9 (0.51) CYP2C9NPSR1GLO1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 CYP2C9 3001/4885NPSR1 324/4885GLO1 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.